Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. (noting a discrepancy in the request metadata which listed "Gyre Therapeutics, Inc.") on June 14, 2018, regarding events occurring on June 13, 2018. The filing details the results of the Company's 2018 Annual Meeting of Stockholders, including the election of directors and the approval of new equity incentive plans.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on stockholder voting results and the authorization of equity plans.
Material Changes and Corporate Actions
- 2018 Omnibus Incentive Plan Approval: Stockholders approved the 2018 Plan, which replaces the 2015 Stock Incentive Plan. The plan authorizes the issuance of up to 1,500,000 shares of common stock for various awards including options, restricted stock, and cash incentives.
- 2018 Employee Stock Purchase Plan (ESPP) Approval: Stockholders approved the 2018 ESPP, authorizing the purchase of up to 120,000 shares of common stock by eligible employees at a discount.
- Director Elections: Nassim Usman, Ph.D., and Errol B. De Souza, Ph.D., were elected as Class III directors for a three-year term.
- Accounting Firm Ratification: The appointment of EisnerAmper LLP as the independent registered public accounting firm for fiscal year 2018 was ratified.
Voting Results and Management Commentary
At the Annual Meeting, 10,382,359 shares were represented, constituting 86.99% of outstanding shares. The voting results for key proposals were as follows:
| Proposal | For | Against | Abstain | Broker Non-Vote |
|---|---|---|---|---|
| Election of Nassim Usman, Ph.D. | 7,578,738 | 3,895 | N/A | 2,799,726 |
| Election of Errol B. De Souza, Ph.D. | 7,186,169 | 396,464 | N/A | 2,799,726 |
| 2018 Omnibus Incentive Plan | 6,060,848 | 1,517,533 | 4,252 | 2,799,726 |
| 2018 Employee Stock Purchase Plan | 7,361,929 | 218,518 | 2,186 | 2,799,726 |
| Say on Pay (Advisory) | 7,498,872 | 79,979 | 3,782 | 2,799,726 |
| Ratification of Auditor (EisnerAmper LLP) | 10,326,451 | 43,499 | 12,409 | 0 |
Management Commentary: The filing notes that the 2018 Plan and 2018 ESPP became effective immediately upon stockholder approval. Outstanding awards under the previous 2015 Plan remain in effect.
Investor Verification Checklist
- Verify the total number of shares authorized under the new 2018 Omnibus Incentive Plan (1,500,000) and the 2018 ESPP (120,000) to assess potential future dilution.
- Review the full text of the 2018 Omnibus Incentive Plan (Exhibit 10.1) and 2018 ESPP (Exhibit 10.2) for specific vesting schedules, exercise prices, and eligibility criteria.
- Confirm the terms of the newly elected directors, Nassim Usman, Ph.D., and Errol B. De Souza, Ph.D., regarding their tenure and committee assignments.
- Note the significant number of broker non-votes (2,799,726) on director elections and equity proposals, indicating shares held in street name where brokers lacked discretionary voting power.